Future perspectives of uveal melanoma blood based biomarkers

Aaron B. Beasley, Fred K. Chen, Timothy W. Isaacs, Elin S. Gray

Research output: Contribution to journalReview articlepeer-review

22 Citations (Web of Science)


Uveal melanoma (UM) is the most common primary intraocular malignancy affecting adults. Despite successful local treatment of the primary tumour, metastatic disease develops in up to 50% of patients. Metastatic UM carries a particularly poor prognosis, with no effective therapeutic option available to date. Genetic studies of UM have demonstrated that cytogenetic features, including gene expression, somatic copy number alterations and specific gene mutations can allow more accurate assessment of metastatic risk. Pre-emptive therapies to avert metastasis are being tested in clinical trials in patients with high-risk UM. However, current prognostic methods require an intraocular tumour biopsy, which is a highly invasive procedure carrying a risk of vision-threatening complications and is limited by sampling variability. Recently, a new diagnostic concept known as “liquid biopsy” has emerged, heralding a substantial potential for minimally invasive genetic characterisation of tumours. Here, we examine the current evidence supporting the potential of blood circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), microRNA (miRNA) and exosomes as biomarkers for UM. In particular, we discuss the potential of these biomarkers to aid clinical decision making throughout the management of UM patients.

Original languageEnglish
Pages (from-to)1511-1528
Number of pages18
JournalBritish Journal of Cancer
Issue number11
Early online date2022
Publication statusPublished - 1 Jun 2022


Dive into the research topics of 'Future perspectives of uveal melanoma blood based biomarkers'. Together they form a unique fingerprint.

Cite this